Introduction
Alcohol use disorders (AUD), one of today's major public health problems, are characterized by compulsive drug-seeking behavior and a loss of control over the intake of alcohol (Garbutt et al., 1999) . Development of AUD largely depends Psychoneuroendocrinology (2013 Psychoneuroendocrinology ( ) 38, 1259 Psychoneuroendocrinology ( -1270 
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on the effects of alcohol on the mesolimbic dopamine system, albeit diverse additional neurobiological mechanisms are involved (for review see (Volkow and Li, 2004; Soderpalm et al., 2009) . Elucidation of the complex neurobiological mechanisms involved for the ability of alcohol to activate the mesolimbic dopamine system may lead to the development of novel treatment strategies for AUD.
Recently it has been shown that signaling systems traditionally involved in regulating food intake, including the hunger regulating peptides such as cholecystokinin, ghrelin, leptin and galanin, also modulates alcohol intake in rodents (Kulkosky, 1984; Blednov et al., 2004; Lewis et al., 2004; Rada et al., 2004; Jerlhag et al., 2009) . These studies raise the possibility that other endocrine signals regulating food intake, such as the gut hormone glucagon-like peptide 1 (GLP-1), may play an important role for the reinforcing properties of alcohol.
Glucagon-like peptide 1 is a circulating incretin peptide that apart from food intake also regulates glucose homeostasis as well as body weight (Kreymann et al., 1987; TangChristensen et al., 1996; Turton et al., 1996) . This peptide is produced in enteroendocrine L-cells of the intestinal mucosa (Novak et al., 1987) and secreted in response to nutrient ingestion (Brubaker and Anini, 2003) . In addition, GLP-1 is also produced in the central nervous system, specifically in neurons in the nucleus tractus solitarius (NTS) that project throughout the brain (Alvarez et al., 1996; Merchenthaler et al., 1999; Baggio and Drucker, 2007; Holst, 2007) . Selective GLP-1 receptor agonists, for example the GLP-1 analogue Exendin-4 (Ex4), exenatide and liraglutide, has emerged as novel pharmacotherapies for type II diabetes because of their enhancing effects on glucose-dependent insulin secretion (Holst et al., 2009) , reduction of gastric emptying and glucagon secretion (Matsuyama et al., 1988; Gutniak et al., 1992; Schirra et al., 1997) . The anorectic effects of GLP-1 are, at least in part, exerted via GLP-1 receptors expressed in the hypothalamus (McMahon and Wellman, 1998) and the NTS (Hayes et al., 2009) . The fact that the GLP-1 receptor also is expressed in the mesolimbic areas (Alvarez et al., 1996; Merchenthaler et al., 1999) , in combination with the findings that common mechanisms regulate food and alcohol intake (Thiele et al., 2004) imply that the GLP-1 signaling system, in addition to homeostatic control of food intake and glucose control, may be involved in alcohol mediated behaviors.
The present series of experiments were undertaken to investigate the potential of the clinically available GLP-1 analogue Ex4 as a novel treatment of AUD. We evaluated the effects of Ex4 on alcohol-induced locomotor stimulation, accumbal dopamine release and condition place preference (CPP) in mice. In addition, we studied the effects of Ex4 on voluntary alcohol intake and alcohol seeking behavior in rats that had consumed ethanol for at least eight months before treatment.
Material and methods

Animals
Adult post-pubertal age-matched male NMRI mice (8-12 weeks old and 25-40 g body weight; B&K Universal AB, Sollentuna, Sweden) were used. All mice were group housed and maintained at a 12/12 h light/dark cycle (lights on at seven am). Tap water and food (Normal chow; Harlan Teklad, Norfolk, England) were supplied ad libitum, except during the experimental setups.
Adult post-pubertal age-matched male Rcc Han Wistar rats (Harlan, Horst, Netherlands) were used for the intermittent access 20% alcohol two-bottle-choice drinking paradigm as well as operant alcohol self-administration procedure. Rats in the two-bottle choice experiment were maintained on a 12 h reversed light dark cycle (lights off at 10 a.m.) and rats in the operant self-administration experiments were maintained on a regular 12 h light-dark cycle (lights on at seven am). Food and water were available ad libitum, except for short periods during initial training in the operant self-administration paradigm. All rats were housed individually in high Macrolon III cages covered with filter tops (Tecniplast, Italy) and maintained at 20 8C with 50% humidity. The study was carried out in strict accordance with the recommendations in the Swedish Animal Welfare Act and all experiments were approved by the Swedish Ethical Committee on Animal Research in Gothenburg and Stockholm for the studies in mice and rats, respectively. All efforts were made to minimize animal suffering, and to reduce the number of animals used. All animals were allowed to acclimatize at least one week before the start of the experiments.
Drugs
The 96% alcohol (Solveco AB, Stockholm, Sweden) was diluted to a 20% (vol/vol) solution using tap water for the two-bottlechoice and operant self-administration experiments. Exendin-4 (Tocris Bioscience, Bristol, UK) is a peptide with the amino acid sequence HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSS GAPPPS. Exendin-4 has previously been established as a GLP-1 receptor agonist (Thorens et al., 1993) and distribution studies show that the CNS binding of Ex4 is identical to GLP-1 (Goke et al., 1995) . The Ex4 dose used in the alcohol related experiments conducted in mice was selected based on the results from the present locomotor study, where 2.4 mg/kg was the highest dose that did not affect locomotor activity per se. In the rats, the doses of 0.3 and 2.4 mg/kg were initially selected based on previous studies (Hayes et al., 2008; Dickson et al., 2012) . However, a pilot experiment showed that the highest dose (2.4 mg/kg) had a sedative effect in our rats that had voluntarily been consuming ethanol for at least nine months before the Ex4 treatment (data not shown). Therefore, the doses of 0.3 and 1.2 mg/kg were used in the experiments conducted in rats that had voluntarily consumed alcohol for at least eight months before testing. In all experiments the selected doses did not affect the rodents gross behavior. Exendin-4 was dissolved in vehicle (0.9% sodium chloride) and stored in aliquots at -20 degrees C before use. The Ex4 stock-solution was thawed before each treatment occasion and administered intra peritoneal (IP) 10 min prior the start of each experiment. A balanced or within subject design was used for all drug challenges.
Locomotor activity experiments
Locomotor activity was recorded as described previously (Jerlhag et al., 2006) . In brief, locomotor activity was registered in eight sound attenuated, ventilated and dim lit locomotor boxes (420 mm Â 420 mm Â 200 mm, Kungsbacka mät-och reglerteknik AB, Fjärås, Sweden). Five by five rows of photocell beams, at the floor level of the box, creating photocell detection allowed a computer-based system to register the activity of the mice. Locomotor activity was defined as the accumulated number of new photocell beams interrupted during a 60 min period.
The mice were allowed to habituate to the locomotor activity box 1 h prior to drug challenge. To identify an Ex4 dose that did not affect the general gross or locomotor behavior, a dose response study (Ex4 1.2, 2.4 or 4.8 mg/kg or vehicle, n = 8 per treatment group) was conducted. Each mouse received one injection 10 min before the start of the test session. In a separate experiment, the effects of the optimal Ex4 dose (2.4 mg/kg, IP), determined in the dose response study, on alcohol-induced (1.75 g/kg, IP) locomotor stimulation were investigated. Ex4 was administered 10 min prior to alcohol and the activity registration started 5 min after the last injection. Each mouse received one treatment combination (vehicle/vehicle, Ex4/vehicle, alcohol/vehicle or Ex4/alcohol; n = 8 per treatment combination) and was only subjected to one experimental trial.
In vivo microdialysis and dopamine release measurements
For measurements of extracellular dopamine levels, mice were implanted unilaterally with a microdialysis probe positioned in the nucleus accumbens. The surgery was performed as described in detail previously (Jerlhag et al., 2006) . In brief, the mice were anesthetized with isofluran (Isofluran Baxter; Univentor 400 Anaesthesia Unit, Univentor Ldt., Zejtun, Malta), placed in a stereotaxic frame (David Kopf Instruments; Tujunga, CA, USA) and kept on a heating pad to prevent hypothermia. The skull bone was exposed and one hole for the probe and one for the anchoring screw were drilled. The probe was randomly alternated to either the left or right side of the brain. The coordinates of 1.5 mm anterior to the bregma, AE0.7 lateral to the midline and 4.7 mm below the surface of the brain surface was used for the nucleus accumbens (Franklin and Paxinos, 1996) . The exposed tip of the dialysis membrane (20 000 kDa cut off with an o.d./i.d. of 310/220 mm, HOSPAL, Gambro, Lund, Sweden) of the probe was 1 mm. All probes were surgically implanted two days prior to the experiment. After surgery the mice were kept in individual cages (Macrolon III).
The effect of systemic administration of Ex4 (2.4 mg/kg, IP) on alcohol-induced (1.75 g/kg, IP) accumbal dopamine release was investigated using microdialysis in freely moving mice. On the day of the experiment the probe was connected to a microperfusion pump (U-864 Syringe Pump; AgnThós AB) and perfused with Ringer solution at a rate of 1.5 ml/min. After 1 h of habituation to the microdialysis set-up, perfusion samples were collected every 20 min. The baseline dopamine level was defined as the average of three consecutive samples before the first alcohol or vehicle (saline, IP) challenge (Time 0). This initial alcohol-challenge was given to establish that all mice included in the experiment would respond with an alcohol-induced release of accumbal dopamine. The challenge-induced increase in accumbal dopamine was calculated as the percent increase from baseline. Nine consecutive 20-min samples were collected after the initial challenge. At 190 min the mice were injected with Ex4 or vehicle (second challenge) and 10 min later vehicle or a second injection of alcohol (1.75 g/kg, IP) was administered (third challenge; 200 min) and followed by collection of four 20-min samples. Collectively the following treatment groups (n = 8 in each group) were created: alcohol-vehicle-alcohol (Alc-VehAlc), alcohol-Ex4-alcohol (Alc-Ex4-Alc), alcohol-vehicle-vehicle (Alc-Veh-Veh) and vehicle-Ex4-vehicle (VehEx4-Veh).
The dopamine levels in the dialysates were determined by HPLC with electrochemical detection. A pump (Gyncotec P580A; Kovalent AB; V. Frölunda, Sweden), an ion exchange column (2.0 mm Â 100 mm, Prodigy 3 mm SA; Skandinaviska GeneTec AB; Kungsbacka, Sweden) and a detector (Antec Decade; Antec Leyden; Zoeterwoude, The Netherlands) equipped with a VT-03 flow cell (Antec Leyden) were used. The mobile phase (pH 5.6), consisting of sulfonic acid 10 mM, citric acid 200 mM, sodium citrate 200 mM, 10% EDTA, 30% MeOH, was vacuum filtered using a 0.2 mm membrane filter (GH Polypro; PALL Gelman Laboratory; Lund, Sweden). The mobile phase was delivered at a flow rate of 0.2 ml/min passing a degasser (Kovalent AB), and the analyte was oxidized at +0.4 V.
After the microdialysis experiments were completed, the mice were decapitated, and probes were perfused with pontamine sky blue 6BX to facilitate probe localization. The brains were mounted on a vibroslice device (752 M Vibroslice; Campden Instruments Ltd., Loughborough, UK) and cut in 50 mm sections. The location of the probe was determined by gross observation using light microscopy. The exact position of the probe was verified (Franklin and Paxinos, 1996) and only mice with correct placements were used in the statistical analysis.
Conditioned place preference
To evaluate the effects of Ex4 on the rewarding effects of alcohol, CPP tests were performed in mice as previously described (Jerlhag et al., 2009) . In brief, a two-chambered CPP apparatus, with 45 lx illumination and distinct visual and tactile cues was used. One compartment was defined by black and white striped walls and by a dark laminated floor whereas the other had a white painted wooden floor and walls of wooden texture. The procedure consisted of preconditioning (day 1), conditioning (days 2-5), and post-conditioning (day 6). At preconditioning, mice were injected IP with vehicle and was placed in the chamber with free access to both compartments during 20 min to determine the initial place (or side) preference. Conditioning (20 min per session) was done using a biased procedure in which alcohol (1.75 g/ kg) was paired with the least preferred compartment and vehicle with the preferred compartment. All mice received one alcohol and one vehicle injection every day and the injections were altered between morning and afternoon in a balances design. At post-conditioning, mice were injected with Ex4 (2.4 mg/kg, IP) or an equal volume of vehicle solution and 10 min later placed on the midline between the two compartments with free access to both compartments for 20 min (creating the following treatment groups; Alc-Veh and Alc-Ex4). A control group of animals were subjected to the same procedure but received only vehicle injections throughout the conditioning (non-alcohol conditioned control group: creating the following treatment groups Veh-Veh and Veh-Ex4).
The subsequent CPP experiment, in a separate group of mice, aimed at investigating the effects of repeated Ex4 treatment during the conditioning on alcohol-induced CPP. In these experiments Ex4 (2.4 mg/kg, IP) or vehicle was administered 10 min prior to the alcohol injection on each of the four conditioning days (creating the following treatment groups; Veh-Alc or Ex4-Alc). In a control experiment mice were subjected to the same procedure but received vehicle injections instead of alcohol throughout the conditioning (non-alcohol conditioned control group; creating the following treatment groups; Veh-Veh and Ex4-Veh). In both these experiments the mice were untreated at the post-conditioning session.
Condition place preference was calculated as the difference in % of total time spent in the drug-paired (i.e. least preferred) compartment during the post-conditioning and the pre-conditioning session.
2.6. Operant alcohol self-administration 2.6.1. Apparatus Testing was conducted in standard operant conditioning chambers (Med Associates Inc, Georgia, VT, USA) enclosed in ventilated, sound-attenuating cubicles. Each chamber housed two retractable levers on the right wall with a cup liquid receptacle placed centrally between them. A house light was present on the wall opposite the levers and remained on at all times during the operant session. Stimulus lights were present above each lever. An apparatus to emit a tone under specific operant conditions was also present. Upon correct (active) lever press(es), the stimulus light above the active (right) lever was illuminated for 3 s and was accompanied by a 3 s tone to reinforce availability of reward in the dipper receptacle. Stimulus, fluid delivery, and operant responses were all controlled and recorded by Med-PC IV software (Med Associate Inc, Georgia, VT, USA).
Training phase
Rats (n = 24) were trained to self-administer 20% alcohol without sucrose fading (Steensland et al., 2012) . Four weeks of intermittent-access to 20% alcohol in the home cage (Wise, 1973; Simms et al., 2008) were followed by two 14 h-overnight-sessions in the operant chamber where the rats were rewarded with a reinforcer of 0.1 ml of 20% alcohol after a single lever press on the right (active) lever (FR1 protocol of reinforcement). An orange scent was present in the operant chamber and a light and a tone were presented when pressing the active lever and served as alcohol-associated cues. Rats were then trained daily for 45 min on the FR1 protocol on 10 consecutive days. A FR3 protocol (three active lever presses required for reward) was then introduced and sessions were reduced to 30 min. After approximately two months the rats were trained only three times per week (Monday, Wednesday and Friday) but instead the sessions were increased to 60 min. An inactive lever (no reinforcer, tone, light or olfactory stimuli) was present throughout the training sessions as a measure of nonspecific behavioral activity. The rats were kept on the FR3 schedule for approximately five months and thereafter subjected to extinction. To minimize the number of animals used, in line with the recommendations in the Swedish Animal Welfare Act, the rats participating in the progressive ratio (PR) test in the present study underwent testing evaluating the effects of the monoamine stabilizer (-)-OSU6162 on cue-induced reinstatement and ethanol seeking under PR schedule (Steensland et al, Biological Psychiatry 2012) before subjected to the Ex4 PR test. To prevent carry over effects between the experiments, we allowed a wash out period of two weeks on regular FR1 sessions three times a week between the (-)-OSU6162 and the Ex4 tests. The rats returned to baseline FR1 responding for 20% alcohol between the tests (22.9 AE 2.7 and 24.8 AE 2.7 active lever presses (mean of three consecutive sessions) before (-)-OSU6162 and Ex4 PR-testing, respectively). When the effect of Ex4 on alcohol seeking behavior under PR schedule was evaluated, the rats had been consuming alcohol for approximately nine months. Seven out of the 24 rats failed to meet the criteria of <0.6 g alcohol/kg body weight per session and were excluded from the PR test.
Progressive ratio testing
The PR method was adapted from (Bowers et al., 2008; Steensland et al., 2010) . In brief, during the PR test, the response requirement for each subsequent reward increases according to an exponential function; PR = 5 Â e(0.1 Â number of reinforcement previously earned) À 5. The PR session started with the cup filled with alcohol and then the PR schedule proceeded with a schedule of 1, 2, 2, 3, 4, 5, 6, 7, 9, 10, 12, 13, 15, 17, 20, 22, 25, 38, 32, 36, 40, 45, and 50 . If the rat did not emit any lever presses for 3 min, there were 20 s timeout (houselights off and levers retracted) followed by a compound cue consisting of tone and light during 3 s. If the rat continued not to emit any lever presses after the timeout, the re-cues continued with 3 min apart for up to 5 iterations. The maximum time each rat had on the PR test were 60 min but if the rat did nothing during a period of 15 min or after five consecutive recues, the program was turned off automatically. The breakpoint was defined as the total number of lever presses established in the last successfully completed ratio during the session.
Injections of Ex4 (1.2 mg/kg) or vehicle were given 10 min prior the start of the PR test session. The PR test was performed once a week during two weeks and each rat received both Ex4 and vehicle in a counter balanced order. Thus, each rat served as its own control. Regular FR1 sessions were run on the days between the progressive ratio tests (Friday and Monday).
Intermittent access 20% alcohol two-bottlechoice drinking paradigm
The intermittent access 20% alcohol two-bottle-choice drinking paradigm induces voluntary intake of high amounts of alcohol (Wise, 1973; Simms et al., 2008) and pharmacological relevant blood alcohol concentrations (Simms et al., 2008; Carnicella et al., 2009) . In brief, the rats (n = 20) were given free access to one bottle of 20% alcohol and one bottle of water during three 24-h-sessions per week (Mondays, Wednesdays and Fridays), approximately 10 min after the lights went out in a reversed light/dark cycle room. The rats had unlimited access to two bottles of water between the alcohol-access-periods. Bottles were weighed at 1, 4 and 24 h after the fluids were presented and measurements were taken to the nearest 0.1 g. The bodyweight of each rat was measured daily prior to bottle presentation, to allow for calculating the grams of alcohol intake per kilogram of body weight (g/kg). The preference for alcohol over water (the ratio of alcohol to total fluid intake) was calculated at all time points. Administration of Ex4 began after the rats had voluntarily consumed high amounts of alcohol (4.5 AE 0.3 g/ kg/24 h) for approximately eight months. The rational for long-term alcohol exposure was to mimic the human context, where AUD is developed following long-term cycles of consumption of high amounts of alcohol and periods of abstinence. Each rat received each Ex4 dose or vehicle over a three-week-test period according to a Latin square design, with seven days between each injection. Thus each animal served as its own control.
Statistical analysis
Locomotor activity data in the Ex4 dose response were evaluated by a one-way ANOVA followed by Bonferroni post-hoc tests. The microdialysis experiments were evaluated by a two-way ANOVA followed by Bonferroni post-hoc test for comparisons between different treatments and specifically at given time points. The CPP data were evaluated by an unpaired t-test. The data from intermittent access 20% alcohol two-bottle-choice drinking paradigm were analyzed by one-way ANOVA, followed by a Newman-Keuls post hoc analysis. The data from the operant alcohol self-administration was analyzed by a paired t-test. Data are presented as mean AE SEM. A probability value of P < 0.05 was considered as statistically significant, except in the locomotor activity testing's where P < 0.0125 was considered significant since a Bonferroni post-hoc test was used.
Results
Dose-response effects of Ex4 on locomotor activity in mice
A statistically significant overall effect of Ex4 treatment on locomotor activity was observed (F(3,28) = 13.08, P < 0.001; n = 8 per group). Post hoc analysis revealed that the highest Ex4 dose (4.8 mg/kg) increased the locomotor activity compared to vehicle (P < 0.001) while the lower Ex4 doses (2.4 and 1.2 mg/kg) had no significant effect on locomotor activity compared to vehicle (P > 0.05; Veh = 126.0 AE 7.7, Ex4 (1.2 mg/kg) = 124.9 AE 23.6, Ex4 (2.4 mg/kg) = 154.8 AE 10.6, Ex4 (4.8 mg/kg) = 268.0 AE 26.1).
Effects of Ex4 on alcohol-induced locomotor stimulation and accumbal dopamine release in mice
An overall main effect of treatment was found on locomotor activity in mice following systemic administration of alcohol (1.75 g/kg) and Ex4 (2.4 mg/kg) (F(3,27) = 18.52, P < 0.001; n = 7-8 per group). As shown in Fig. 1A , posthoc analysis revealed that alcohol significantly increased the locomotor activity compared to vehicle (P < 0.001). This alcohol-induced locomotor stimulation activity was significantly reduced by pre-treatment with a single injection of Ex4 (P < 0.01), at a dose that alone had no significant effect on locomotor activity compared to vehicle treatment (P > 0.05). Figure 1 Exendin-4 attenuates alcohol-induced locomotor stimulation and accumbal dopamine release in mice. (A) Alcohol-induced (1.75 g/kg IP) locomotor stimulation was attenuated by a single injection of Ex4 (2.4 mg/kg IP) (n = 8 in each group; ***P < 0.001, as indicated in figure, one-way ANOVA followed by a Bonferroni post-hoc test). (B) The alcohol-induced (1.75 g/kg IP) increase in accumbal dopamine release was absent in Ex4-(2.4 mg/kg IP) but not in vehicle-pre-treated mice (n = 8 in each group). Arrows represent time points of injection of alcohol, Ex4 or vehicle. Initial injections of alcohol increased dopamine release in all groups (Alc-Veh-Alc (square), Alc-Ex4-Alc (triangle) and for Alc-Veh-Veh (circle)) in comparison to the group initial receiving vehicle treatment (Veh-Ex4-Veh (rhomb)). Pretreatment with Ex4 prior to the second injection of alcohol significantly attenuated the alcohol-induced increase in dopamine release (Alc-Veh-Alc vs Alc-Ex4-Alc). There was no difference in response between Alc-Veh-Veh and Alc-Ex4-Alc (**P < 0.01 and ***P < 0.01, two-way ANOVA followed by a Bonferroni post-hoc test). All values represent mean AE SEM. Arrow shows time for injections.
Exendin-4 and alcohol mediated behaviors
Accumbal microdialysis measurements of dopamine in mice revealed an overall main effect of treatment (F(3,13) = 1.14, P < 0.001), time (F(16,357) = 3.98, P < 0.001) and a significant interaction of treatment Â time time (F(16,357) = 1.99, P < 0.001). In the first part of the experiment the responsiveness to alcohol (1.75 g/kg) per se was investigated. Initial injections of alcohol caused a significant increase in accumbal dopamine release compared to vehicle treatment at time point 60 (P < 0.001) and 80 min (P < 0.01) for the future Alc-Veh-Alc group, and at time point 60 min for the future Alc-Ex4-Alc (P < 0.01) and AlcVeh-Veh (P < 0.05) group, respectively (Fig. 1B) . In the subsequent part of the experiment, administration of Ex4 (2.4 mg/kg, at 190 min) 10 min prior to the second alcohol injection (Alc-Veh-Alc), significantly attenuated the alcohol-induced accumbal dopamine release compared to vehicle pre-treatment (Alc-Ex4-Alc) at time point 220 (P < 0.001), 240 (P < 0.01), 260 (P < 0.01) and 280 (P < 0.001), Fig. 1B . In contrast, Ex4 when administered alone had no significant effect on accumbal dopamine release (P > 0.05; Alc-Ex4-Veh vs Alc-Veh-Veh).
Effects of Ex4 on alcohol-induced conditioned a place preference in mice
In the first CPP experiment, the alcohol-induced (1.75 kg/kg) (Alc-Veh) CPP was significantly attenuated by an acute single injection of Ex4 (2.4 mg/kg) (Alc-Ex4) on the post-conditioning day compared to vehicle injection (P < 0.01, n = 8 in each group; Fig. 2A ). In the second series of CPP experiments, conducted in vehicle conditioned mice, Ex4 per se did not affect CPP compared to vehicle injections (Veh-Ex4: 12.5 AE 5.3%; Veh-Veh: 11.2 AE 4.1%, P > 0.05, n = 8 in each group). In the third series of CPP experiments we showed that repeated Ex4-treatment (4 injections in total; Ex4-Alc) compared to vehicle treatment (Veh-Alc) during the 4 conditioning days, blocked the ability of alcohol to induce a CPP (P < 0.05, n = 8 in each group; Fig. 2B ). In the fourth series of CPP experiments, conducted in vehicle conditioned mice (i.e. non-alcohol conditioned control animals), we showed that co-treatment with Ex4 (Ex4-Veh) during conditioning did not induce a significant CPP response compared to vehicle co-treatment (Veh-Veh) (Veh-Veh = À0.2 AE 9.7%, Ex4-Veh = 20.2 AE 5.3%, P > 0.05, n = 8 in each group).
Effects of Ex4 on voluntary alcohol intake using the intermittent access model in rats
The effect of Ex4 on voluntary alcohol intake was evaluated in rats that had consumed high amounts of alcohol (4.5 AE 0.3 g/kg/24 h, n = 20) for eight months prior to the test. There was an overall main effect of Ex4 treatment on alcohol intake (g/kg) at all time-points analyzed (1 h: F(2,19) = 18.69, P < 0.001; 4 h: F(2,19) = 12.95, P < 0.001; 24 h: F(2,19) = 8.236, P < 0.01). Post hoc analysis revealed a significant reduction in alcohol intake following treatment with the highest Ex4 dose (1.2 mg/kg) compared to vehicle at all time-points (24 h : Fig. 3 A; 1 h and 4 h: Table 1 ). However, the lower Ex4 dose (0.3 mg/kg) had no significant effect on alcohol intake (24 h: Fig. 3A ; 1 h and 4 h: Table 1 ). Furthermore, Ex4 treatment induced an overall main effect on water intake at all time points (1 h: F(2,19) = 4.39, P < 0.05; 4 h: F(2,19) = 8.45, P < 0.001; 24 h: F(2,19) = 5.42, P < 0.01). Post hoc analysis revealed a significant increase in water intake following treatment with both the high and low Ex4 dose compared to vehicle at the 24 h time point (Fig. 3B) . In contrast, at the 1 and 4 h time points, the high dose of Ex4 induced a significant decrease in water intake ( Table 1 ). The decreased alcohol intake and increased water intake at the 24 h time point resulted in an overall main effect of Ex4 treatment on alcohol preference (F(2,19) = 7.83, P < 0.01). Post hoc analysis revealed a reduction in preference for alcohol after administration of both the high and low dose Ex4 compared to vehicle treatment at the 24 h time point (Fig. 3C) . However, no overall main effect on alcohol preference was observed at the other time points (4 h: F(2,19) = 1.72, P > 0.05; 1 h: F(2,19) = 0.92, P > 0.05; Table  1 ). There was no overall main effect on the total fluid intake following Ex4 treatment at the 24 h time point (F(2,19) = 2.82, P > 0.05) (Fig. 3D) . However, an overall main effect was found at 4 h (F(2,19) = 25.46, P < 0.001) and at 1 h (F(2,19) = 16.67, P < 0.001). Post hoc analysis revealed a significant reduction in total fluid intake following administration of the high Ex4 dose (1.2 mg/kg) compared to vehicle treatment both at 1 h and 4 h ( Table 1) .
To evaluate if Ex4 treatment induced a rebound increase in ethanol consumption after the treatment was terminated, the alcohol intake during the drinking session initiated 48 h after Ex4 administration was evaluated. No overall main Figure 2 Exendin-4 attenuates alcohol-induced conditioned place preference in mice. (A) The alcohol-induced (1.75 g/kg IP) condition place preference (CPP) was attenuated by an acute single IP injection of Ex4 (2.4 mg/kg IP) in mice (n = 8 in each group, *P < 0.05, unpaired t-test). (B) Treatment of Ex4 during alcohol conditioning blocked the ability of alcohol to induce a CPP in mice (n = 8 in each group, *P < 0.05, unpaired t-test). All values represent mean AE SEM. Figure 3 Exendin-4 reduces alcohol intake in rats following eight months of intermittent access to alcohol. (A) Ex4 (1.2 mg/kg IP) significantly reduced alcohol intake (g/kg/24 h) compared to vehicle treatment in rats that had voluntarily consumed alcohol for eight months before the treatment. The lower dose of Ex4 (0.3 mg/kg IP) had no significant effect on alcohol consumption. (B) Ex4 (0.3 and 1.2 mg/kg IP) increased the intake of water (ml/24 h) in rats compared to vehicle treatment. (C) Ex4 (0.3 and 1.2 mg/kg IP) significantly reduced in alcohol preference (%/24 h) compared to vehicle treatment. (D) Neither dose of Ex4 affected the total fluid intake (ml/24 h) compared to vehicle treatment. All values represent mean AE SEM (n = 20, *P < 0.05, **P < 0.01 and ***P < 0.001 compared to vehicle, one-way ANOVA followed by Newman-Keuls post hoc test). Table 1 Effects of two different doses of Ex4 or vehicle treatment on alcohol (g/kg), water (ml) and total fluid (ml) intake as well as preference (%) at 1 and 4 h time points. Data represent mean AE SEM (n = 20, **P < 0.01 and ***P < 0.001 compared to vehicle, one-way ANOVA followed by Newman-Keuls post hoc test).
Treatment
Alcohol Intake (g/kg) Water Intake (ml) Preference (%) Total Fluid Intake (ml) Exendin-4 and alcohol mediated behaviorseffect on the alcohol intake was found at any time points during the first drinking session following the Ex4 treatment (1 h: F(2,19) = 0.73, P > 0.05; 4 h: F(2,19) = 0.26, P > 0.05; 24 h: F(2,19) = 1.67, P > 0.05).
Effects of Ex4 on alcohol seeking using progressive ratio test
The effects of Ex4 on ethanol seeking behavior were evaluated using an operant self-administration paradigm under PR-schedule in rats (n = 16). Following approximately nine months of voluntary alcohol exposure, treatment with Ex4 (1.2 mg/kg) significantly reduced the number of active lever presses (P < 0.01, Fig. 4A ) as well as the breakpoint (P < 0.001, Fig. 4B ) compared to vehicle treatment. In addition, the number of inactive lever presses was significantly reduced from 1.5 AE 0.3 to 0.8 AE 0.3 following vehicle-and Ex4-treatment, respectively (P < 0.05).
Discussion
While previous studies have shown that the incretin peptide GLP-1 is a physiological regulator of food intake and glucose homeostasis (Baggio and Drucker, 2007; Holst, 2007) , the present results provide novel evidence that GLP-1 receptors also are involved in regulating the reinforcing properties of alcohol. Specifically, we found that the GLP-1 analogue, Ex4, suppressed the alcohol-induced locomotor stimulation and accumbal dopamine release in mice. Furthermore, our finding that Ex4 attenuated alcohol-induced CPP in mice as well as voluntary alcohol consumption and alcohol seeking behavior in rats provide evidence that GLP-1 signaling is involved in alcohol reward. Thus, GLP-1 receptors may provide a unique target for the development of pharmacological treatment strategy for AUD. Development of AUD largely depends initially on the effects of alcohol on the mesolimbic dopamine system (for review see (Tupala and Tiihonen, 2004) ). The present findings show that Ex4 suppresses established alcohol-induced effects on the mesolimbic dopamine system including alcohol-induced locomotor stimulation, accumbal dopamine release and CPP (Engel et al., 1988; Sanchis-Segura and Spanagel, 2006) . Gluagon like peptide-1 receptors are expressed in reward regulating brain areas such as the ventral tegmental area and the nucleus accumbens (Alvarez et al., 1996; Merchenthaler et al., 1999) and endogenous GLP-1-containing-fibers from the NTS specifically target these reward areas (Rinaman, 2010; Alhadeff et al., 2012) . We therefore hypothesize that Ex4's ability to regulate the reinforcing properties of alcohol are mediated via GLP-1 receptors within these reward nodes. Exendin-4 was administered systemically in the present series of experiments, thus it is possible that the observed Ex4 effects on alcohol-mediated behaviors could be due to peripheral rather than central effects. This possibility is supported by the finding that vagal afferent signaling is required for the ability of peripherally administered GLP-1 to reduce spontaneous meal size (Ruttimann et al., 2009 ). In addition, the findings that Ex4 enhance glucose-dependent insulin secretion (Holst et al., 2009) and that insulin modulate reward induced by psychostimulant drugs in rodents (for review see (Daws et al., 2011) ), indicate that the effects of Ex4 on alcohol reward could be insulin-dependent. However, Ex4 readily crosses the bloodbrain barrier (Kastin and Akerstrom, 2003) and has anorexigenic properties independent of administration route (Kanoski et al., 2011) . In addition, it was recently shown that Ex4 reduces CPP for and intake of palatable food as well as decrease the motivation for sucrose following peripheral as well as intra-ventral tegmental and -accumbal administration (Alhadeff et al., 2012; Dickson et al., 2012) . Furthermore, intra-accumbal injections of GLP-1 receptor antagonists cause hyperphagia, indicating that endogenous GLP-1 signaling within brain reward areas is important for food intake (Dossat et al., 2011) . GLP-1 signaling via GLP-1 receptors found in other areas such as the hypothalamus and the lower brain stem, which previously have been shown to mediate GLP-1's anorexigenic (McMahon and Wellman, 1998; Hayes et al., 2009 ) and glucose regulating effects (Sandoval et al., 2008) , could also be of importance for alcohol reinforcement. Based on these findings, we hypothesis that the effects of Ex4 alcohol related behaviors seen in the present studies, are mediated through a central mechanism. However, the exact circuits Figure 4 Exendin-4 reduces the operant self-administration of alcohol in rats following nine months of alcohol exposure. (A) Exendin-4 (1.2 mg/kg IP) treatment significantly reduces the number of active lever presses and (B) decreases the breakpoint (n = 16, **P < 0.001 compared to vehicle paired t-test). All values represent mean AE SEM.
through which GLP-1 receptor signaling modulates alcohol reward and alcohol consumption needs to be further elucidated.
The present study shows that GLP-1 analogues, including Ex4, may be of clinical interest for the treatment of AUD. Our results highlight four characteristics desirable for an AUD medication. First, Ex4 reduced voluntary alcohol intake in rats that had consumed alcohol for eight months before treatment using the intermittent access 20% alcohol twobottle choice model (Simms et al., 2008) . Importantly, this drinking model seems to predict the efficacy of potential novel AUD medications in a clinical population, at least for varenicline (Steensland et al., 2007; McKee et al., 2009; Mitchell et al., 2012) . Secondly, Ex4 treatment decreased the breakpoint for alcohol lever presses using the PR test in the operant self-administration model, indicating that GLP-1 receptors are involved in the regulation of alcohol seeking behavior as well as in the strength of alcohol's reinforcing properties. Although there was a drop in the activity at the inactive lever following Ex4 treatment in the PR test, it should be noted that the vehicle responding was 1.5 AE 0.3 lever presses compared to 0.8 AE 0.3 following the Ex4 treatment. In addition, the Ex4 treatment did not affect the gross behavior of the rats. Thus, these results indicate that the effect on the inactive lever was not due to a general decrease in motility. Thirdly, we showed that Ex4 did not induce a rebound increase in alcohol intake after the treatment was terminated, tentatively an important feature of an AUD therapeutic. Finally, Ex4 blocked the rewarding properties of alcohol in mice but had no effect per se on accumbal dopamine release, locomotor activity or CPP, indicating that GLP-1 receptors are specifically important for alcoholmediated behaviors and deserves to be evaluated as a potential novel treatment target for AUD.
We hypothesize that the attenuating effects of Ex4 on alcohol reinforcement are mediated through a direct effect on the GLP-1 receptor. However, some studies show that Ex4 may not be selective for the GLP-1 receptor (Malendowicz et al., 2003; Sonne et al., 2008; Barrera et al., 2009) , implying that there are other possible mechanisms of action for Ex4 that are GLP-1 receptor independent. Given that we have previously shown that ghrelin signaling is required for alcohol mediated behaviors in rodents (Jerlhag et al., 2009; Landgren et al., 2012) and that Ex4 administration has been shown to suppress plasma levels of ghrelin in fasted rats (Perez-Tilve et al., 2007) , it cannot be excluded that our findings are independent of GLP-1 receptor activation. However, the findings that GLP-1 receptor antagonist blocks the ability of Ex4 to reduce the motivation to consume sucrose (Dickson et al., 2012) , supports our hypothesis that the reinforcing properties of rewards such as alcohol are mediated directly via GLP-1 receptors. Nevertheless, regardless mechanism of action, the present data are of clinical importance since other GLP-1 analogues including exenatide and liraglutide, are FDA-approved for diabetes mellitus and could therefore potentially be used also for the treatment of AUD.
The present experiments show that Ex4, in addition to decreasing voluntary alcohol consumption, reduces water and total fluid intake at the 1 and 4 h time points raising the possibility that the ability of Ex4 to reduce alcohol consumption may be due to an unselective effect on fluid intake. Another tentative explanation of the reduced fluid intake at the 1 and 4 h time point following Ex4 treatment could possibly be nausea since Ex4 previously has been shown to induce a condition taste aversion at a similar dose range as used in the present study (Kanoski et al., 2012) . To exclude this possibility we evaluated the effects of Ex4 on conditioned place aversion, which has been suggested to correlate to conditioned taste aversion (Cagniard and Murphy, 2012) . The present results show that repeated Ex4 treatment during conditioning did not induce a conditioned place aversion in vehicle-paired mice, indicating that the Ex4 doses used were not aversive or induced nausea. Moreover, the findings that Ex4 blocks parameters reflecting alcohol reward, i.e. locomotor stimulation, accumbal dopamine release and CPP, imply that the rewarding properties of alcohol were specifically targeted. In accordance with these findings, recent studies have shown that Ex4 attenuates amphetamine-as well as cocaine-induced locomotor stimulation in rodents Graham et al., 2012) . Taken together with the notion that the mesolimbic dopamine system increases the incentive value of motivated behaviors (Robinson and Berridge, 1993) , it is possible that GLP-1 analogues may decrease the incentive value for motivated behaviors in relation to alcohol and other drugs of abuse. Supportively, GLP-1 analogues have been found to reduce the motivation for palatable food (Raun et al., 2007; Dickson et al., 2012) , further supporting a role for GLP-1 signaling in drug-induced reward and possibly in the pathophysiology of AUD. Additionally, repeated co-treatment with Ex4 during the alcohol conditioning phase and acute Ex4 treatment on the test day, blocked alcohol-induced CPP in mice providing evidence that GLP-1 receptors are involved in both the acquisition and retrieval of reward related memory, which are other important aspects of the addiction process.
Our present findings show, to our knowledge for the first time, an involvement of the GLP-1 receptors in alcohol reinforcement. These results support previous studies showing that gut-brain signaling systems has the ability to regulate the intake of both food and alcohol (Thiele et al., 2004) . For example, other endocrine signals from the periphery and the gut including leptin and cholecystokinin reduces, whereas galanin increases, food as well as alcohol consumption (Blednov et al., 2004; Lewis et al., 2004; Rada et al., 2004) . In addition, the orexigenic peptide ghrelin is required for alcohol-reward, alcohol intake as well as for the motivation to consume alcohol (Jerlhag et al., 2009; Kaur and Ryabinin, 2010; Landgren et al., 2012) . Supportively, gastric bypass has recently been shown to reduce alcohol intake in both humans and rats . A finding that has been correlated to reduced ghrelin and increases GLP-1 plasma levels . However, population studies, without correlations to plasma levels of these gut-brain hormones are inconclusive and show that gastric bypass can reduce, increase or have no effect on alcohol consumption in humans (for review see (Ertelt et al., 2008) ). Collectively, the present findings raise an important question regarding the physiological role of gut-brain signals and their ability to influence not only food intake but, also having a broader role in modulating the reward system in general and reward related processes in relation to alcohol in particular. These endocrine signals may therefore be potential target for development of novel treatment strategies for of AUD. Interestingly, selective GLP-1 receptor agonists are used as treatments for type II diabetes because of their enhancing effects on glucose-dependent insulin secretion (Holst et al., 2009) , reduction of gastric emptying as well as on reduction of glucagon secretion (Matsuyama et al., 1988; Gutniak et al., 1992; Schirra et al., 1997) .
In conclusion, our present results showing that Ex4 attenuates alcohol-induced locomotor stimulation, accumbal dopamine release and CPP as well as reduces alcohol intake and alcohol-seeking behavior in rodents, indicate that GLP-1 analogues deserves to be evaluated as potential therapeutics for AUD, an entirely novel aspect. 
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